Online inquiry

IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6022MR)

This product GTTS-WQ6022MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL12B gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002187.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3593
UniProt ID P29460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6022MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4780MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ4941MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ2847MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ12147MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ3637MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ15187MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ3785MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ6835MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW